How to Get Mounjaro Online in 2026
Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
No verified affiliate offer for this medication
This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.
Mounjaro (tirzepatide 2.5–15 mg weekly) is FDA-approved for type 2 diabetes, the same molecule as Zepbound, which carries the obesity indication. Mounjaro vs Zepbound is purely an indication and labeling distinction; pharmacies cannot freely substitute. Telehealth platforms prescribe Mounjaro for on-label diabetic use; for weight loss they direct patients to Zepbound. Cash-pay retail runs $1,000–$1,200/mo; the Lilly savings card can drop commercial copays to ~$25/mo.
Mounjaro is a once-weekly subcutaneous tirzepatide injection (2.5, 5, 7.5, 10, 12.5, 15 mg) FDA-approved May 2022 for adults with type 2 diabetes. Mechanism: dual GIP and GLP-1 receptor agonist, the only dual incretin currently on the market. Available in pen and KwikPen formats. Pharmacologically identical to Zepbound; legally and commercially separate SKUs.
Adults with type 2 diabetes seeking glycemic control beyond metformin or after failing on a single GLP-1, particularly those who want the strongest weight-loss-as-side-effect profile (mean -7 to -12% body weight in SURPASS trials). Strong fit for patients with both T2D and obesity who don't qualify for Zepbound through their insurance. Same MTC/MEN-2 contraindications as Zepbound.
Standard titration: 2.5 mg (weeks 1–4) → 5 mg (weeks 5–8) → escalating every 4 weeks if tolerated up to 15 mg. KwikPen and pen formats. Cash-pay $1,000–$1,200/mo without insurance. Lilly savings card drops commercial copays to ~$25/mo for covered patients. Side-effect profile per SURPASS-2: nausea (22%), diarrhoea (16%), decreased appetite (10%), constipation (10%). Lower side-effect rates than Zepbound 15 mg because diabetic patients typically titrate slower and many stay at 5–10 mg.
Verified Offers for Mounjaro
What the Studies Actually Show
Mounjaro is FDA-approved tirzepatide for type 2 diabetes. The evidence below comes from the SURPASS program (registration trials), the SURMOUNT obesity program (relevant to expected weight effects in patients with T2D), and the FDA prescribing information.
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
Same active ingredient (tirzepatide), same dose strengths, same titration schedule. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management and OSA in obese adults. Insurance plans treat them as separate drugs because of the indication; pharmacies cannot substitute one for the other without a new prescription.
Can I get Mounjaro for weight loss?
Most reputable telehealth platforms will prescribe Zepbound rather than Mounjaro for weight-loss-only patients, because Zepbound has the appropriate FDA indication. Insurance plans will typically reject Mounjaro prescriptions written for non-diabetic patients. Patients with both T2D and obesity may be prescribed Mounjaro on-label and benefit from weight loss as a documented side effect.
How much does Mounjaro cost without insurance?
Retail cash-pay $1,000–$1,200/mo. Unlike Zepbound, there is no LillyDirect cash-pay vial channel for Mounjaro, the cheaper vial format is reserved for the obesity indication. The Lilly savings card can drop commercial insurance copays to ~$25/mo for covered T2D patients but does not help uninsured patients.
Does Medicare cover Mounjaro?
Yes, Medicare Part D covers Mounjaro for type 2 diabetes. It does not cover Mounjaro (or Zepbound) for weight loss alone, though Zepbound is now covered when prescribed for OSA in obese patients. Medicaid coverage varies by state.
Is Mounjaro stronger than Ozempic?
In the SURPASS-2 head-to-head trial (NEJM 2021): Mounjaro 15 mg achieved an HbA1c reduction of -2.30 percentage points vs -1.86 for semaglutide 1 mg, with greater weight loss (-12.4 kg vs -6.2 kg). For most diabetic patients with both glycemic-control goals and obesity, Mounjaro outperforms Ozempic, though side-effect rates are slightly higher.
Which telehealth providers prescribe Mounjaro?
Diabetes-focused telehealth (PlushCare, Sesame Care, and primary-care platforms) prescribe Mounjaro on-label for T2D patients. Obesity-focused platforms (TrimRx, MEDVi, Eden, FuturHealth) generally direct weight-loss patients to Zepbound rather than Mounjaro. Diabetic patients should specify their diagnosis upfront to avoid being routed to Zepbound.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.